Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine

被引:31
作者
Bergstrom, RF [1 ]
Goldberg, MJ [1 ]
Cerimele, BJ [1 ]
Hatcher, BL [1 ]
机构
[1] Wishard Mem Hosp, Lilly Lab Clin Res, Lilly Res Labs, Eli Lilly & Co, Indianapolis, IN 46202 USA
关键词
D O I
10.1016/S0009-9236(97)90084-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To assess whether fluoxetine and its metabolite, norfluoxetine, are inhibitors of the metabolism of CYP3A substrates. Background: Because inhibition of the first-pass metabolism of terfenadine may be associated with fatal arrhythmia, we assessed the possibility that fluoxetine inhibits this metabolism as a model for CYP3A drug interactions. Methods: Male subjects (n = 12) were given two single doses of 60 mg terfenadine alone (treatment 1) and again after the eighth dose in a 9-day regimen of 60 mg fluoxetine once a day (treatment 2). Blood samples, collected up to 48 hours after each terfenadine dose, were assayed for terfenadine and terfenadine acid metabolite. The assay limits of quantification were 0.1 ng/ml and 5.0 ng/ml, respectively. Noncompartmental pharmacokinetic data for terfenadine and terfenadine acid metabolite were compared between treatments. Results: Mean value +/- SD plasma concentrations of fluoxetine (165 +/- 45 ng/ml) and norfluoxetine (83 +/- 23 ng/ml) achieved after the eighth dose did not cause a significant change in terfenadine acid metabolite pharmacokinetics. All terfenadine concentrations were less than 5 ng/ml and they were approximately 30% lower after fluoxetine pretreatment compared with terfenadine alone. The area under the concentration-time curve for terfenadine was lower after fluoxetine administration, a statistically significant difference, but the peak concentration of terfenadine was not significantly different. Because most antihistaminic activity after terfenadine administration is attributed to its acid metabolite, the small decrease in terfenadine concentration is not clinically significant. No subject discontinued the drugs because of an adverse event. Conclusion: Fluoxetine did not inhibit the metabolism of terfenadine and is unlikely to affect the metabolism of terfenadine or other drugs that are CYP3A substrates.
引用
收藏
页码:643 / 651
页数:9
相关论文
共 30 条
[1]  
Bazett HC, 1920, HEART-J STUD CIRC, V7, P353
[2]   THE EFFECTS OF RENAL AND HEPATIC-DISEASE ON THE PHARMACOKINETICS, RENAL TOLERANCE, AND RISK-BENEFIT PROFILE OF FLUOXETINE [J].
BERGSTROM, RF ;
BEASLEY, CM ;
LEVY, NB ;
BLUMENFIELD, M ;
LEMBERGER, L .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1993, 8 (04) :261-266
[3]   QUANTIFICATION AND MECHANISM OF THE FLUOXETINE AND TRICYCLIC ANTIDEPRESSANT INTERACTION [J].
BERGSTROM, RF ;
PEYTON, AL ;
LEMBERGER, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (03) :239-248
[4]   DETERMINATION OF THE METABOLITES OF TERFENADINE IN HUMAN URINE BY THERMOSPRAY LIQUID-CHROMATOGRAPHY MASS-SPECTROMETRY [J].
CHEN, TM ;
CHAN, KY ;
COUTANT, JE ;
OKERHOLM, RA .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1991, 9 (10-12) :929-933
[5]   DETERMINATION OF TERFENADINE AND TERFENADINE ACID METABOLITE IN PLASMA USING SOLID-PHASE EXTRACTION AND HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION [J].
COUTANT, JE ;
WESTMARK, PA ;
NARDELLA, PA ;
WALTER, SM ;
OKERHOLM, RA .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1991, 570 (01) :139-148
[6]  
GARTEIZ DA, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1185
[7]   Effect of dirithromycin on human CYP3A in vitro and on pharmacokinetics and pharmacodynamics of terfenadine in vivo [J].
Goldberg, MJ ;
Ring, B ;
DeSante, K ;
Cerimele, B ;
Hatcher, B ;
Sides, G ;
Wrighton, S .
JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (12) :1154-1160
[8]   THE EFFECTS OF KETOCONAZOLE ON THE INTESTINAL METABOLISM AND BIOAVAILABILITY OF CYCLOSPORINE [J].
GOMEZ, DY ;
WACHER, VJ ;
TOMLANOVICH, SJ ;
HEBERT, MF ;
BENET, LZ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) :15-19
[9]   FLUOXETINE IMPAIRS CLEARANCE OF ALPRAZOLAM BUT NOT OF CLONAZEPAM [J].
GREENBLATT, DJ ;
PRESKORN, SH ;
COTREAU, MM ;
HORST, WD ;
HARMATZ, JS .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (05) :479-486
[10]   TERFENADINE-KETOCONAZOLE INTERACTION - PHARMACOKINETIC AND ELECTROCARDIOGRAPHIC CONSEQUENCES [J].
HONIG, PK ;
WORTHAM, DC ;
ZAMANI, K ;
CONNER, DP ;
MULLIN, JC ;
CANTILENA, LR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (12) :1513-1518